CA
ADAP

Claro Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Claro Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,607
Closed -$35K – 158
2018
Q4 		$35K Buy
+2,607
New +$19.2K 0.03% 410

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Claro Advisors's ADAP Position: Q1 2019 in Review

Claro Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 2,607 shares — an estimated $35K sold.

Claro Advisors first reported a position in ADAP in Q4 2018 and held it in 1 quarter. The position peaked at $35K in Q4 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • Claro Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Claro Advisors sold 2,607 Adaptimmune Therapeutics shares in Q1 2019, an estimated $35K.
  • Claro Advisors first reported a position in Adaptimmune Therapeutics in Q4 2018 and held it in 1 quarter.
  • Claro Advisors's Adaptimmune Therapeutics position peaked at $35K in Q4 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.